EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced an exclusive promotion and marketing agreement with LEO Pharma for detailing OTREXUP™ (methotrexate) to dermatologists for symptomatic control of severe recalcitrant psoriasis in adults. Under the terms of the agreement, Antares may receive up to a total of $20 million in milestone payments including an upfront payment of $5 million. Antares Pharma will record all product revenue associated with future dermatology prescriptions and pay LEO Pharma a percentage of OTREXUP™ net sales generated in dermatology. LEO Pharma will be responsible for promotion and marketing activities in dermatology.
Help employers find you! Check out all the jobs and post your resume.
